Atopic Dermatitis Clinical Trials Market is Expected to Elevate to a Value of .84 Billion by the End of 2030Posted by Sona Kulkarni on April 2nd, 2024 Atopic Dermatitis Clinical Trials Market Growth & Trends The global atopic dermatitis clinical trials market is expected to reach USD 4.84 billion by 2030 and expand at a CAGR of 11.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. Advancements in biotechnology and medicine, growing prevalence of atopic dermatitis, increasing investments by pharmaceutical companies in the development of novel drugs, rising partnerships and acquisitions among CROs and sponsor companies, technological advancements in clinical research, growing pipeline of atopic dermatitis products, and globalization of clinical trials are few of the factors supporting the lucrative growth of the global market during the forecast period. For pharmaceutical companies, innovation and easy access to clinics are critical factors. Furthermore, pharmaceutical and biopharmaceutical companies increasingly focus on developing novel drugs for treating atopic dermatitis. For instance, the U.S. FDA stated that several potential therapeutics will be launched in the coming years to treat atopic dermatitis. A few of the potential biologics likely to enter the market include Rocatinlimab by -Kyowa Kirin Co., Ltd., lebrikizumab by Eli Lilly and Company, CM310 by Keymed Biosciences, tozorakimab by AstraZeneca and several others. Hence, the increasing pipeline of therapeutics is one of the major factors augmenting market growth. Furthermore, the increasing prevalence of atopic dermatitis is a significant catalyst propelling the market growth. Atopic dermatitis is a chronic inflammatory skin condition that has witnessed a notable rise in incidence globally, affecting individuals of all ages. In 2022, approximately 223 million individuals are coping with atopic dermatitis, per the Global Burden of Disease (GBD) 2022 report. Among them, approximately 43 million falls within the age group of 1 to 4 years. This surge in prevalence has created a compelling need for more effective and targeted treatment options. As a result, pharmaceutical companies, research institutions, and healthcare organizations are increasingly investing in clinical trials to explore novel therapeutic interventions. Moreover, several companies are focusing on inorganic strategic initiatives such as mergers and acquisitions to enhance their position in the industry. For instance, in March 2022, Pfizer Inc. announced the acquisition of Arena Pharmaceuticals, a clinical-stage company dedicated to developing innovative potential therapies for various immuno-inflammatory diseases, including atopic dermatitis. Request a free sample copy or view report summary: Atopic Dermatitis Clinical Trials Market Report Atopic Dermatitis Clinical Trials Market Report Highlights
Access Press Release@ https://www.grandviewresearch.com/press-release/global-atopic-dermatitis-clinical-trials Atopic Dermatitis Clinical Trials Market Segmentation Grand View Research has segmented the atopic dermatitis clinical trials market on the basis of molecule type, study design, phase and region: Atopic Dermatitis Clinical Trials Molecule Type Outlook (Revenue, USD Million; 2018 - 2030)
Atopic Dermatitis Clinical Trials Study Design Outlook (Revenue, USD Million; 2018 - 2030)
Atopic Dermatitis Clinical Trials Phase Outlook (Revenue, USD Million; 2018 - 2030)
Atopic Dermatitis Clinical Trials Region Outlook (Revenue, USD Million; 2018 - 2030)
List of Key Players in the Atopic Dermatitis Clinical Trials Market
About Grand View Research Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare. Like it? Share it!More by this author
|